Core Viewpoint - The company, Zhixiang Jintai, has entered into exclusive cooperation agreements with subsidiaries of Kangzhe Pharmaceutical Holdings and RXILIENT Medical for two monoclonal antibody injections, GR2001 and GR1801, which will provide significant financial benefits and exclusive commercialization rights in various regions [1][2]. Group 1: GR2001 Injection Agreement - Zhixiang Jintai will receive upfront payments and milestone payments totaling up to approximately 260 million RMB for the GR2001 injection [1] - Kangzhe Pharmaceutical will obtain exclusive commercialization rights for GR2001 in mainland China, while RXILIENT will have exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa [1] - The company will also earn revenue based on net sales adjustments from regions outside mainland China and will pay promotional service fees to Kangzhe Pharmaceutical based on sales revenue in mainland China [1] Group 2: GR1801 Injection Agreement - Zhixiang Jintai will receive upfront payments and milestone payments totaling up to approximately 250 million RMB for the GR1801 injection [2] - Kangzhe Pharmaceutical will gain exclusive commercialization rights for GR1801 in mainland China, while RXILIENT will have exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa [2] - Similar to the GR2001 agreement, the company will earn revenue based on net sales adjustments from regions outside mainland China and will pay promotional service fees to Kangzhe Pharmaceutical based on sales revenue in mainland China [2]

Core Viewpoint - The company, Zhixiang Jintai, has entered into exclusive cooperation agreements with Kangzhe Pharmaceutical Holdings and its subsidiary, Tibet Kangzhe Pharmaceutical Development, for the commercialization of two monoclonal antibody injections, GR2001 and GR1801, in various regions [1][2] Group 1: GR2001 Injection Agreement - Tibet Kangzhe will obtain exclusive commercialization rights for GR2001 in mainland China, while RXILIENT will have exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa, excluding mainland China [1] - The company will receive upfront payments and milestone payments totaling up to approximately 260 million RMB, along with sales revenue from mainland China and supply income based on net sales in the Asia-Pacific region and the Middle East and North Africa [1] - The company will pay promotional service fees to Tibet Kangzhe based on sales revenue in mainland China as per the agreement [1] Group 2: GR1801 Injection Agreement - Tibet Kangzhe will obtain exclusive commercialization rights for GR1801 in mainland China, while RXILIENT will have exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa, excluding mainland China [2] - The company will receive upfront payments and milestone payments totaling up to approximately 250 million RMB, along with sales revenue from mainland China and supply income based on net sales in the Asia-Pacific region and the Middle East and North Africa [2] - The company will pay promotional service fees to Tibet Kangzhe based on sales revenue in mainland China as per the agreement [2]

Core Insights - The company, Zhixiang Jintai, has signed exclusive cooperation agreements with Kangzhe Pharmaceutical Holdings and RXILIENT MEDICAL for two monoclonal antibody injections, GR2001 and GR1801, which will provide significant financial benefits and market access in various regions [1][2]. Group 1: Agreement Details - The agreements include upfront payments and milestone payments, with potential earnings of up to approximately RMB 260 million for GR2001 and RMB 250 million for GR1801 [1][2]. - Kangzhe will hold exclusive commercialization rights for both products in mainland China, while RXILIENT will have exclusive licensing rights in the Asia-Pacific region and the Middle East and North Africa [1][2]. Group 2: Product Information - GR2001 is a recombinant humanized monoclonal antibody targeting the C-terminal heavy chain of Tetanus Neurotoxin (TeNT), classified as a Class 1 therapeutic biological product, providing passive immunity by blocking TeNT entry into neurons [2]. - GR1801 is a recombinant fully human bispecific antibody targeting the glycoprotein of the Rabies Virus (RABV), also classified as a Class 1 therapeutic biological product, designed to prevent rabies by blocking the virus from binding to receptors before the active immunity from rabies vaccines takes effect [3].

Core Viewpoint - Zhixiang Jintai (688443.SH) has signed exclusive cooperation agreements with Tibet Kangzhe and RXILIENT for the commercialization of GR2001 and GR1801 monoclonal antibody injections, which is expected to positively impact the company's performance and long-term development [1] Group 1: Partnership Details - Tibet Kangzhe will obtain exclusive commercialization rights for the two products in mainland China [1] - RXILIENT will receive exclusive licensing rights for the Asia-Pacific region, as well as the Middle East and North Africa, excluding mainland China [1] Group 2: Financial Implications - Zhixiang Jintai will receive an upfront payment and milestone payments totaling approximately 510 million RMB [1] Group 3: Future Outlook - The cooperation is anticipated to have a positive effect on the company's performance and long-term growth [1] - There are uncertainties related to the drug registration process and commercialization risks [1]

重庆智翔金泰生物制药股份有限公司 自愿披露关于唯康度塔单抗注射液以及斯乐韦米单抗 注射液商业化合作的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688443 证券简称：智翔金泰 公告编号：2025-043 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"、"智翔金泰"） 与康哲药业控股有限公司（以下简称"康哲药业"）之附属公司西藏康哲药业发展 有限公司（以下简称"西藏康哲"）和 RXILIENT MEDICAL PTE. LTD.（以下简称 "RXILIENT"）就唯康度塔单抗注射液（GR2001 注射液）以及斯乐韦米单抗注射 液（GR1801 注射液）分别签订独家合作协议（以下简称"协议"）。根据协议，公 司将获得首付款、里程碑付款并获得其商业化推广等服务，西藏康哲将获得上述两 款产品在中国大陆的独家商业化权，RXILIENT 将获得上述两款产品除中国大陆之 外的亚太地区及中东、北非的独家许可权。具体内容公告如下。 一、协议概述 根据《GR2001 注射液独家合作协议》，西藏康哲将获得唯康度塔 ...

Core Viewpoint - The company, Zhixiang Jintai, has signed exclusive cooperation agreements with Kangzhe Pharmaceutical and RXILIENT for the commercialization of two monoclonal antibody injections, GR2001 and GR1801, which will provide significant financial benefits and market access in various regions [1][2][3] Group 1: Agreements and Financial Terms - The agreements grant exclusive commercialization rights for GR2001 to Tibet Kangzhe in mainland China, while RXILIENT receives exclusive licensing rights for the Asia-Pacific region and the Middle East and North Africa [1] - Zhixiang Jintai will receive upfront and milestone payments totaling up to approximately 260 million RMB for GR2001, along with revenue from sales in mainland China and supply income based on net sales in other regions [1] - For GR1801, Tibet Kangzhe will also obtain exclusive commercialization rights in mainland China, with RXILIENT securing similar rights in the Asia-Pacific region and the Middle East and North Africa, and Zhixiang Jintai will receive payments up to approximately 250 million RMB [2] Group 2: Product Details - GR2001 is a recombinant humanized monoclonal antibody targeting the C-terminal of the Tetanus Neurotoxin (TeNT), classified as a Class 1 therapeutic biological product, providing passive immunity by blocking TeNT from entering neuronal cells [2] - GR1801 is a recombinant fully human bispecific antibody targeting the glycoprotein of the Rabies Virus (RABV), also classified as a Class 1 therapeutic biological product, designed to prevent rabies by blocking the virus's interaction with receptors before the vaccine can take effect [3]

Core Viewpoint - The company has entered into exclusive collaboration agreements for two monoclonal antibody injections, GR2001 and GR1801, with subsidiaries of Kangzhe Pharmaceutical and RXILIENT MEDICAL, indicating a strategic move to enhance its product portfolio and market presence in specific regions [1] Group 1 - The company will receive upfront payments and milestone payments as part of the collaboration agreements [1] - Kangzhe Pharmaceutical will obtain exclusive commercialization rights for the two products in mainland China [1] - RXILIENT MEDICAL will gain exclusive licensing rights for the products in the Asia-Pacific region, as well as the Middle East and North Africa [1]

证券之星消息，9月19日，智翔金泰（688443）融资买入1435.15万元，融资偿还1223.5万元，融资净买 入211.66万元，融资余额1.39亿元，近3个交易日已连续净买入累计2716.21万元，近20个交易日中有14 个交易日出现融资净买入。 融资融券余额1.39亿元，较昨日上涨1.59%。 | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-09-19 | 1.39亿 | 217.92万 | 1.59% | | 2025-09-18 | 1.37亿 | 1495.44万 | 12.24% | | 2025-09-17 | 1.22亿 | 1009.57万 | 9.01% | | 2025-09-16 | 1.12亿 | 577.75万 | 5.44% | | 2025-09-15 | 1.06亿 | 729.87万 | 7.38% | | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-09-19 | 211.66万 | 1. ...

此前几日，智翔金泰在新药研发上取得重大进展。9月11日晚间，公司公告称，其"泰利奇拜单抗注射液 (GR1802注射液)"用于成人中、重度特应性皮炎适应症III期临床试验达到主要终点指标，且已向国家药 品监督管理局(NMPA)药品审评中心(CDE)提交该适应症新药上市申请并获受理。此外，在感染性疾病 治疗领域，智翔金泰自主研发的全球首个狂犬病被动免疫双特异性抗体GR1801(斯乐韦米单抗)注射液 和抗破伤风毒素单克隆抗体GR2001注射液，均已向CDE提交新药上市申请，且已顺利获得受理，有望 为狂犬病和破伤风的治疗带来新突破。 智翔金泰是一家创新驱动型生物制药企业，自2015年成立以来，专注于抗体药物的研发、生产及商业 化，业务涵盖自身免疫性疾病、感染性疾病和肿瘤等重大疾病领域。目前，公司拥有在研产品14个，凭 借自主研发构建起六大核心技术平台，为持续创新提供技术支撑。此次多款新药上市申请获受理，以及 参与行业业绩说明会，彰显了公司在创新药研发领域的实力和积极与投资者沟通的态度。 中证报中证网讯(王珞)9月16日，智翔金泰(688443)参加2025年半年度科创板创新药行业集体业绩说明 会，此次会议通过上海证券 ...

Core Points - The company will participate in the 2025 Investor Online Collective Reception Day and Semi-Annual Performance Briefing on September 25, 2025, to enhance investor relations and corporate governance [1][2] - The company has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection, which is aimed at treating vitiligo [4][5] - GR2301 injection is a recombinant fully human anti-IL-15 monoclonal antibody developed by the company, targeting autoimmune diseases caused by IL-15 expression disorders [6][7] Group 1 - The event will be held online, allowing investors to interact with the company's senior management from 15:00 to 17:00 on the specified date [1][2] - The clinical trial approval for GR2301 injection indicates compliance with relevant drug registration requirements, allowing the company to proceed with its clinical trials [4][5] - There are currently no approved antibody drugs targeting IL-15 globally, highlighting the potential market opportunity for GR2301 injection [7] Group 2 - The company emphasizes its commitment to transparency and legal responsibility regarding the accuracy and completeness of the information disclosed [1][4] - The GR2301 injection is classified as a Class 1 therapeutic biological product, indicating its innovative nature and potential high value in the market [5][6] - The company will continue to follow regulatory requirements and disclose further developments regarding the clinical trial and product registration process [8]